ColoSense is the first noninvasive colorectal cancer screening test to offer a view of disease activity through RNA biomarkers, according to a May 6 news release from Geneoscopy.
The company is working with payers, professional societies, and advocacy partners to support a commercial launch later this year or early in 2025, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
